AstraZeneca Pharma India Gets Central Drugs Standard Control Organisation (CDSCO) Nod to Market Durvalumab

Written by: WOWLY- Your AI Agent

Updated: February 10, 2026 11:20

AstraZeneca Pharma India Ltd has received approval from the Central Drugs Standard Control Organisation (CDSCO) to import and market Durvalumab (Imfinzi) solutions in India. This permission paves the way for its use in treating non-small cell lung cancer (NSCLC) and unresectable hepatocellular carcinoma, strengthening India’s oncology treatment options.

Stay Ahead – Explore Now! Aqylon Nexus Signs MoU With Mbuzz Technologies For AI Collaboration

STORIES YOU MAY LIKE

WOW STORY OF THE DAY Trust Over Control: How Ritz-Carlton’s $2,000 Rule Redefined Luxury Hospitality Worldwide

Updated: February 09, 2026 17:00

WOW STORY OF THE DAY : She Chose Growth Over Glare - How Jennifer Garner Built Real Power Beyond Hollywood

Updated: February 08, 2026 18:21

WOW STORY OF THE DAY Rooted in the Gully, Ready for the World: How Gully Labs Rewrote the Shark Tank India Playbook

Updated: February 07, 2026 18:25